7TM Pharma initiates clinical studies of potential blockbuster  

Denmark's 7TM Pharma has initiated phase I/II clinical trials of a drug candidate for the treatment of obesity

7TM Pharma, a Danish biotech company based north of Copenhagen has initiated phase I/II clinical trials of TM30338, a drug for the treatment of obesity. TM30338 has a novel mode of action and is derived from the company's proprietary platform of Y receptor peptides.

Thue Schwartz, research director of 7TM Pharma says that obesity is recognised as a global health problem, but currently available treatment is restricted to a few drugs with limited effect. "If 7TM Pharma's programme is developed all the way to a completed product, it will become a blockbuster", he says. More than 300 million people worldwide are clinically obese and the number is growing rapidly. The news is reported by national daily newspaper Berlingske Tidende and on 7TM Pharma's website.

7TM Pharma is a drug discovery and development company which has a pipeline of advanced programmes in its main therapeutic focus area, obesity. The biotech company's pipeline also include programmes on well validated targets in allergy/inflammation, therapeutic angiogenesis and cardiovascular diseases. 7TM Pharma expects to initiate preclinical development of at least one additional drug candidate this year. Investors in 7TM Pharma are Novo A/S, LODH Immunology Fund, Dansk Innovationsinvestering, Alta Partners, Index Ventures and Baker-Tisch Investments.

Link > 7TM Pharma 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×